Browsing Research publications by Author "Buszko, Katarzyna"
Now showing items 1-3 of 3
-
Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction : A prospective, observational, single-centre study
Adamski, Piotr; Sikora, Joanna; Laskowska, Ewa; Buszko, Katarzyna; Ostrowska, Małgorzata; Umińska, Julia M; Sikora, Adam; Skibińska, Natalia; Sobczak, Przemysław; Adamska, Urszula; Rość, Danuta; Kubica, Aldona; Paciorek, Przemysław; Marszałł, Michał P; Navarese, Eliano P; Gorog, Diana A; Kubica, Jacek (2017-10-12)BACKGROUND: Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation ... -
Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial
Kubica, Jacek; Adamski, Piotr; Gorog, Diana A.; Kubica, Aldona; Jilma, Bernd; Budaj, Andrzej; Siller-Matula, Jolanta M.; Gurbel, Paul A.; Alexopoulos, Dimitrios; Badarienė, Jolita; Dąbrowski, Paweł; Dudek, Dariusz; Giannitsis, Evangelos; Horszczaruk, Grzegorz; Jaguszewski, Miłosz J.; James, Stefan; Jeong, Young Hoon; Kryjak, Michał; Niezgoda, Piotr; Ostrowska, Małgorzata; Patti, Giuseppe; Romanek, Janusz; Di Somma, Salvatore; Specchia, Giuseppe; Tantry, Udaya; Gąsior, Mariusz; Tycińska, Agnieszka; Wojakowski, Wojciech; Buszko, Katarzyna; Gil, Robert; Gruchała, Marcin; Kasprzak, Jarosław; Kleinrok, Andrzej; Legutko, Jacek; Lesiak, Maciej; Navarese, Eliano P. (2021-09-30) -
Metabolism of ticagrelor in patients with acute coronary syndromes.
Adamski, Piotr; Buszko, Katarzyna; Sikora, Joanna; Niezgoda, Piotr; Barańska, Malwina; Ostrowska, Małgorzata; Paciorek, Przemysław; Navarese, Eliano P; Gorog, Diana; Kubica, Jacek (2018-09-06)Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation ...